nctId,briefTitle,conditions,specialty,clean_text
NCT03148210,Undiagnosed COPD and Asthma Population Study (UCAP),Asthma; COPD,Pulmonology,Inclusion: * Subjects at least 18 years old; * Subjects who score > or = to 6 points on The Asthma Screening Questionnaire or > 19.5 points on The COPD Diagnostic Questionnaire; * Subjects who have given written informed consent to participate in this trial in accordance with local regulations; * Subjects able to perform pre and post bronchodilator spirometry to measure lung function; Additional Inclusion Criteria for RCT: Those subjects who have undiagnosed airflow obstruction (i.e. Asthma will be diagnosed in subjects with airflow obstruction whose FEV1 improves by > 12% and 200 ml after bronchodilator and COPD will be diagnosed in subjects who do not have a significant bronchodilator response and who exhibit persistent airflow obstruction post bronchodilator) will be asked to consent and participate in the RCT. Exclusion: * Subjects who report a previous physician diagnosis of asthma. * Subjects who report a previous physician diagnosis of COPD * Subjects with any of the following conditions within the past 3 months: Heart attack or hospitalization for other heart problems; Stroke; Aortic or cerebral aneurysm; Detached retina or eye surgery * Subjects who are in the third trimester of pregnancy * Subjects involved in another interventional trial
NCT02294968,The Family Startup Program. A Randomized Controlled Trial of a Universal Group-based Parenting Support Program,First-time Pregnant Women and Their Partners,Other,"Inclusion: -Parents, mothers as well as their partners, expecting their first child in the municipality of Aarhus are eligible for the study. This is because of the universal nature of the original program. Mothers are included if interested regardless of the fathers' decline. Biological fathers, registered partners, as well as non-registered partners are eligible. Exclusion: * Parents are excluded from the study if they are under the age of 18 years * Not capable of managing own legal affairs * Choose not to accept any routine pregnancy scans. These exclusion criteria are chosen to secure that study participants are legally responsible and that we are able to recruit them via the Department of Obstetrics and Gynaecology in connection with the nuchal translucency scan around week 12 * The father or partner is not included if the mother declines participation. The mother can choose to attend the Family Startup Program with a friend (i.e. a sister, friend or neighbor) but friends are not eligible for the study * Finally, individuals are excluded if they are not able to understand the Danish oral presentation of the study information and hence cannot give informed consent"
NCT04078659,Propofol and Magnesium Sulfate Intravenous Infusion During Endoscopic Sinus Surgery,Endoscopic Sinus Surgery,Other,"Inclusion: * American Society of Anesthesiologists Physical Classes I or II Exclusion: * Patients refusal * Patients with hypersensitivity for any drug used in the study including magnesium, propofol or isoflurane * Patients receiving magnesium sulfate supplementation * Patients receiving drugs known to have significant interaction. * Patients with ischemic heart disease * Patients with heart defects * Patients with significant heart failure * Patients with increased intracranial pressure. * Patients with systemic hypertension"
NCT00906997,Colorectal Cancer Screening in Average-risk Population: Immunochemical Fecal Occult Blood Testing Versus Colonoscopy,Colorectal Cancer; Colorectal Neoplasm,Oncology,"Inclusion: * Men and women aged 50-69 years Exclusion: * Personal history of colorectal cancer, colorectal adenoma, colorectal polyposis, or inflammatory bowel disease * Family history of colorectal polyposis, Lynch syndrome or familial colorectal cancer (2 or more first-degree relatives diagnosed with colorectal cancer or one first-degree relative diagnosed with colorectal cancer before the age of 60) * Severe comorbidity * Previous total colectomy * Not signed informed consent to participate"
NCT02830594,"Pembrolizumab and Palliative Radiation Therapy in Treating Patients With Metastatic Esophagus, Stomach, or Gastroesophageal Junction Cancer",Gastric Adenocarcinoma; Gastric Squamous Cell Carcinoma; Gastroesophageal Junction Adenocarcinoma; Metastatic Malignant Neoplasm in the Stomach; Stage IV Esophageal Adenocarcinoma AJCC v7; Stage IV Esophageal Squamous Cell Carcinoma AJCC v7,Other,"Inclusion: * Documented informed consent of the participant * Willing to provide tumor tissue amenable to ultrasound or computed tomography (CT)-guided biopsy for biomarker analyses * Patients with malignant ascites are permitted to participate and provide ascites samples for biomarker analyses * Patents receiving radiation to a single metastatic site in which only the primary tumor is accessible for biopsy by endoscopy will also be eligible * Eastern Cooperative Oncology Group (ECOG) performance status of = = 3 months * Diagnosis of metastatic squamous cell carcinoma and/or adenocarcinoma of the esophagus, gastroesophageal junction, or stomach in need of palliative radiotherapy to the primary tumor or a single metastatic site for symptoms such as pain, dysphagia, and/or gastrointestinal bleeding * Patients with adenocarcinoma histology and known human epidermal growth factor receptor 2 (HER2) overexpressing disease are permitted to participate if the progressed or are intolerant of prior trastuzumab-containing therapy * Measurable metastatic sites of disease outside of the target lesion undergoing palliative radiation based on RECIST 1.1 as assessed by the investigator * Have no limits on prior lines of therapy or may be treatment-naive if in need of palliative RT provided the patient has not received prior anti-programmed cell death protein 1(PD-1), anti-programmed cell death 1 ligand 1 (PD-L1), or anti-programmed cell death 1 ligand 2 (PD-L2) therapy * Absolute neutrophil count (ANC) >= 1,500/mm^3 * Platelets >= 100,000/mm^3 * Hemoglobin >= 9 g/dL * May receive transfusion to meet this goal * Total serum bilirubin = 1.5 x ULN * Albumin >= 2.5 mg/dL * Aspartate aminotransaminase (AST) and alanine aminotransferase (ALT) = = 60 mL/min if creatinine levels > 1.5 x ULN * Glomerular filtration rate (GFR) can also be used in place of creatinine or creatinine clearance (CrCl) * If not receiving anticoagulants: international normalized ratio (INR) OR prothrombin (PT) = 1 year * Male: use an adequate method of contraception starting with the first dose of study therapy through 120 days after the last dose of study therapy Exclusion: * Anti-PD-1, anti-PD-L1, or anti-PD-L2 agents * Prior radiation therapy within the field of the target lesion that in the opinion of the treating radiation oncologist would preclude further palliative radiation to a dose of 30 gray (Gy) * Anti-cancer monoclonal antibody (mAb) within 4 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlier * Chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent * Note: Subjects with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study * Note: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy * Live vaccine within 30 days of planned start of study therapy * Note: Seasonal influenza vaccines for injection are generally inactivated flu vaccines and are allowed; however intranasal influenza vaccines (e.g., Flu-Mist) are live attenuated vaccines, and are not allowed * Immunosuppressive therapy within 7 days prior to the first dose of trial treatment * Investigational device within 4 weeks of the first dose of treatment * Currently receiving an investigational agent * About to undergo palliative radiation for a symptomatic central nervous system (CNS) metastasis * Systemic steroid therapy * Hypersensitivity to pembrolizumab or any of its excipients * Diagnosis of immunodeficiency * Active autoimmune disease that has required systemic treatment in the past 2 years (i.e., with use of disease modifying agents, corticosteroids or immunosuppressive drugs) * Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment * Known history of, or any evidence of active, non-infectious pneumonitis * Current active infection requiring systemic therapy * Known history of active tuberculosis (TB), human immunodeficiency virus (HIV) 1/2, hepatitis B or hepatitis C * Known additional malignancy that is progressing or requires active treatment * Exceptions include basal cell carcinoma of the skin or squamous cell carcinoma of the skin that has undergone potentially curative therapy or in situ cervical cancer * Known active central nervous system (CNS) metastases and/or carcinomatous meningitis * Subjects with previously treated brain metastases may participate provided they are stable, have no evidence of new or enlarging brain metastases, and are not using steroids for at least 7 days prior to trial treatment; this exception does not include carcinomatous meningitis which is excluded regardless of clinical stability * History or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject's participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating investigator * Known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial * Pregnant or breastfeeding (female only)"
NCT01285388,"Safety, Tolerability and Pharmacokinetic Study of MB12066 in Healthy Volunteers",Metabolic Syndrome; Obesity,Other,"Inclusion: 1. Subject is informed of the investigational nature of this study and voluntarily agrees to participate in this study and signs an Institutional Review Board (IRB) - approved informed consent prior to performing any of the screening procedures 2. Healthy Korean male volunteers, age ranged 20 to 45 years (both inclusive) 3. A subject with body weight between 60 kg (inclusive) and 90 kg (exclusive) and body mass index (BMI) between 18.5 (inclusive) and 25 (exclusive). ☞ BMI (kg/m2) = weight (kg) / {height (m)}2 4. Findings within the range of clinical acceptability in medical history and physical examination, and laboratory results within the laboratory reference ranges for the relevant laboratory tests (unless the investigator considers the deviation to be irrelevant for the purpose of the study) Exclusion: 1. A subject with history of allergies including drug allergies (aspirin, antibiotics, etc.), or history of clinically significant allergies 2. A subject with clinical evidence or history of hepatic (including carrier of hepatitis virus), renal, respiratory, endocrine, neurologic, immunologic, hematologic, oncologic, psychiatric, or cardiovascular disease 3. A subject with history of gastrointestinal disease or surgery (except simple appendectomy or repair of hernia), which can influence the absorption of the study drug 4. A subject whose hemoglobin(Hb) level < 12 g/dL 5. A subject with fasting plasma glucose (FPG) level ≤ 70 mg/dL or ≥ 126 mg/dL 6. A subject with HbA1c level ≥ 7.0 mmol/L 7. A subject whose systolic blood pressure (SBP) ≤ 90 mmHg or ≥ 140 mmHg, diastolic blood pressure (DBP) ≤ 40 mmHg or ≥ 90 mmHg or pulse rate (PR) ≥ 100 /min after at least 5 min sitting 8. A subject with history of drug abuse or positive urine drug screening test 9. A subject who has taken any prescribed medication or herbal compounds within 14 days prior to the study drug administration. In addition, a subject who has taken any over-the-counter drug or vitamin supplements within 7 days prior to the study drug administration (However, investigators can judge the subject, who has taken the medications during those periods above, eligible for the trial if all other conditions are satisfied.) 10. A subject who has participated in any other clinical trial either for investigational or marketed drugs within 8 weeks before the study drug administration 11. A subject who has donated or had loss of ≥ 400 mL of blood within 8 weeks prior to start of administration of study drug 12. A subject who consumes more than 21 units of alcohol per week or unable to stop drinking throughout the study period. 13. A smoker (except for whom quitted smoking prior to the drug administration for at least 3 months) 14. A subject who heavily takes caffeine or caffeine-containing products, grapefruit, grapefruit juice, grapefruit-containing products 15. A subject with unusual dietary habit 16. A subject who was previously assigned to treatment during this study 17. The investigator judges the subject not eligible for the study after reviewing clinical laboratory results or other reasons."
NCT00295646,"Tamoxifen Versus Anastrozole, Alone or in Combination With Zoledronic Acid",Breast Cancer,Oncology,"Inclusion: * Premenopausal, hormone receptor-positive patient * Histologically verified (minimally) invasive breast cancer, local radical treatment * 0-9 involved axillary lymph nodes (≥ 10 histologically examined nodes) * Tumor stage: pT1b-3, yT0 or yT1a Exclusion: * T1a, T4d, yT4; M1 * Previous breast tumor irradiation * Previous or concurrent chemotherapy (except for preoperative chemotherapy) * Serum creatinine > 1.5 x UNL or creatinine clearance < 60 ml/min"
NCT03486379,Folfiri as Third Line of Treatment,Gastric Cancer; Ramucirumab; Third Line,Oncology,"Inclusion: * Patients with histologically confirmed, ramucirumab pretreated metastatic gastric cancer who received * Eastern Cooperative Oncology Group performance status ≤2 (ECOG PS) * aged > 18 years * neutrophil count ≥1500/μl * platelet count ≥100 000/μl), * renal (serum creatinine ≤1.5 mg/dl) * liver (serum bilirubin ≤2 mg/dL) functions * normal cardiac function, * absence of second primary tumor other than non-melanoma skin cancer * no concurrent uncontrolled medical illness. Exclusion: * Eastern Cooperative Oncology Group performance status >2 (ECOG PS) * No prior treatment with ramucirumab * operable metastatic disease were excluded from the study * severe cardiac dysfunction, congestive heart failure or a recent myocardial infarction * uncontrolled sites of infection."
NCT00632086,"Evaluate Relative Bioavailability of PA32540 (Asa/Omeprazole), Its Aspirin Component, and Ecotrin® in Healthy Volunteers",Healthy,Other,Inclusion: * Standard for PK * Ages 18-55 years old * Males and females Exclusion: * Standard for PK
NCT05090423,The Effect of Additional Neurodynamic Intervention in Patients With Chronic Ankle Instability,Ankle Sprains,Other,"Inclusion: 1. History of at least two ankle sprains in the same leg, of which the first sprain is more than one year 2. Leading to at least one interrupted day of desired physical activity 3. The Cumberland Ankle Instability Tool (CAIT) ≦ 24 4. Slump test in ankle plantar flexion with inversion: positive Exclusion: 1. Pregnancy 2. Surgical treatments 3. Previous fractures in either lower extremity 4. Any concomitant lower extremity pathology, for example, vascular disease, osteoarthritis and rheumatoid arthritis 5. Significant pain or injury to the lumbar or cervical spine 6. Regular use of medication: anti-inflammatory drugs, painkiller, steroid or muscle relaxants 7. Previous manual therapy or exercise interventions received on the lower extremity within the previous 3 months"
NCT02688608,Pembrolizumab in Anaplastic/Undifferentiated Thyroid Cancer,Anaplastic Thyroid Cancer,Oncology,"1. Be willing and able to provide written informed consent for the trial. 2. Histologically or cytologically confirmed diagnosis of anaplastic thyroid cancer or undifferentiated thyroid cancer. A diagnosis of possible ATC/UTC will be allowed if the clinical presentation is consistent with anaplastic or undifferentiated thyroid cancer. 3. Be ≥ 18 years of age on day of signing informed consent. 4. Have measurable disease based on RECIST 1.1. 5. Be willing to provide tissue from a newly obtained core or excisional biopsy of a tumor lesion. Newly-obtained is defined as a specimen obtained up to 6 weeks (42 days) prior to initiation of treatment on Day 1. Subjects for whom newly-obtained samples cannot be provided (e.g. inaccessible or subject safety concern) may submit an archived sample. 6. Have a performance status of 0-1 on the Eastern Cooperative Oncology Group (ECOG) Performance Scale. 7. Demonstrate adequate organ function as defined in the protocol. , 8. Female subject of childbearing potential should have a negative urine or serum pregnancy within 72 hours prior to receiving the first dose of study medication. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required. 9. Female subjects of childbearing potential should be willing to use 2 methods of birth control or be surgically sterile, or abstain from heterosexual activity for the course of the study through 120 days after the last dose of study medication (Reference Section 5.7.2). Subjects of childbearing potential are those who have not been surgically sterilized or have not been free from menses for > 1 year. 10. Male subjects should agree to use an adequate method of contraception starting with the first dose of study therapy through 120 days after the last dose of study therapy."
NCT06356168,Virtual Reality in End Stage Kidney Disease,End Stage Kidney Disease,Other,Inclusion: * Diagnosis of end stage kidney disease with hemodialysis 3 times per week for at least 1 month Exclusion: * Acutely ill * Active nausea * Epilepsy
NCT04286568,Wald Outreach for Wellness: Blood Pressure Outreach,Pre-hypertension; Hypertension,Other,Inclusion: * Community residents who participate in Day at the Market * Adult individuals 18 years and older whose recorded BP reading is within the pre-hypertensive range 120-139 systolic; 80-89 diastolic * Able to read and understand English Exclusion: * 17 years or younger * BP reading above pre-hypertensive range * Unable to read and understand English
NCT05223842,Family Promoting Positive Emotions Pilot Study,Depression; Anhedonia; Stress; Depressive Disorder; Behavioral Symptoms; Mood Disorders; Mental Disorder; Mood Disturbance,Other,"Inclusion: for mothers: * Age 18 and older who report at least subthreshold current depressive symptoms (> score of 8 on the Patient Health Questionnaire) and moderate COVID-19-related stress * Can read and speak in English. * Have access to a computer with a videoconferencing platform. Inclusion criteria for children: * Age 8-12 years who can participate with their biological mother who is 18 years or older that meets the above criteria. * Can read and speak in English. Exclusion: for mothers: * Current substance use disorder. * Intellectual disabilities. * Diagnosis of mania or bipolar disorder. * Diagnosis of a psychotic disorder (e.g., schizophrenia). * Visual or hearing impairments that interfere with completing study measures and sessions. Exclusion criteria for children: * Diagnoses of autism spectrum disorders or developmental disorders. * Intellectual disabilities. * Diagnosis of mania or bipolar disorder. * Diagnosis of a psychotic disorder (e.g., schizophrenia). * Currently experiencing depressive symptoms. * Visual or hearing impairments that interfere with completing study measures and sessions. * Offspring of mothers who have previously participated in the study with another biological child."
NCT02083068,Evaluation of the Protective Efficacy of a Vaccine Derived From the Synthetic CS Protein of Plasmodium Vivax,Malaria,Other,"Inclusion: * Naïve group Healthy men and women aged 18-45 years. Signing freely and voluntary informed consent , accompanied by two witnesses who also sign. Not have a history of malaria infection. For women, use of adequate contraception from the star restriction to be lifted by a doctor for contraception study. Accept not to travel to areas considered endemic for malaria during Trophies infectious period (1 month ) ( Buenaventura , Tierralta , Pretoria , Tumaco ,Urabá and Bajo Cauca) . Be reachable by phone throughout the study period. Being Duffy positive ( Fy +) . Levels of hemoglobin ( Hb) > 11 g / dl. Availability to participate during the period in which they develop the study. Do not be participating in another clinical study 2. Preimmune group Healthy men and women aged 18-45 years. Signing freely and voluntary informed consent , accompanied by two witnesses who also sign . Having a history of infection (s ) and serological tests for malaria positive for P. vivax. For women, use adequate contraception from the start restriction to be lifted by a doctor for contraception study . Accept not to travel to areas considered endemic for malaria during Trophies infectious period (1 month ) ( Buenaventura , Tierralta , Pretoria , Tumaco Urabá and Bajo Cauca) . Be reachable by phone throughout the study period. Availability to participate during the period in which they develop the study. 3. Voluntary blood donors * Healthy men and women aged 18-45 years. * Be positive diagnosis of P. vivax determined by thick smear examination . * The patient must not have circulating malaria parasites such as P. falciparum or P. malariae . * Have a parasitemia ≥ 0.1 %. by thick smear . * Hb ≥ 9 g / dL at the time of diagnosis of malaria. * The patient must have the capacity to provide informed consent freely and voluntarily . Should be illiterate may assert its decision to participate by putting their fingerprint in the format consent. Minors who are between 15 and 17 and wishing to participate must sign the informed consent and one of its Parents must sign the informed consent, accompanied by 2 witnesses who also sign Exclusion: * Step 1 * Negative IFAT (< 1:20) for P. vivax on screening tests * Other criteria used in the case of naive volunteers, except a history of having lived in an endemic area for the past 6 months. Step 2 Patients that have chronic or acute disease, different from malaria by P. vivax. Having a history of disease or clinical conditions that according to medical criteria might increase significantly the risk related with participation on this study Hemoglobin levels <9 g/dL at the time of recruitment Have received antimalarial treatment before the diagnosis"
NCT00279305,Rituximab in New Onset Type 1 Diabetes,Type 1 Diabetes Mellitus,Endocrinology," Between the ages of 8 and 45 years  Within 3 months of diagnosis of type 1 diabetes  Have presence of at least one diabetes-related autoantibody  Must have stimulated C-peptide levels of at least 0.2 pmol/ml measured during a mixed meal tolerance test (MMTT) within one month of randomization  If female with reproductive potential, willing to avoid pregnancy and undergo pregnancy testing while participating in the study  Have not received an immunization for at least one month  Must be willing to comply with intensive diabetes management  Must weigh at least 25 kg at study entry"
NCT03259568,Effects of rTMS on Human Brain Activity Measured With fMRI,Human Brain Activity,Neurology,1. Age between 18-30. 2. Use of effective method of birth control for women of childbearing capacity. 3. Willing to provide informed consent.
NCT04277013,Ultrasound Assessment of Gastric Content in Fasted Pregnant Women,Gastric Ultrasound; Fasting ( 6H for Solid ; 2H for Clear Fluid ); Pregnant Women,Other,"Inclusion: An subject must fulfill all of the following criteria in order to be eligible for study enrollment: * Aged at least 18 years old * Pregnant women * Fasted ( at least 6h for solid , 2h for clear fluid ) Exclusion: * Previous Bariatric surgery / upper gastro-intestinal surgery * Adult under protection"
NCT01505582,Inspiratory Muscle Training and Low Back Pain,Inspiratory Muscle Training; Low Back Pain; Respiratory Disorders,Other,"Inclusion: individuals with low back pain: * Age: 18-45 years old * At least 1 year of low back pain with/without referred pain in buttock/thigh * At least 3 episodes of disabling low back pain * At least a score of 20% on the Oswestry Disability Index * Willingness to sign the informed consent Exclusion: * History of major trauma and/or major orthopedic surgery of the spine, the pelvis or the lower quadrant * One of the following conditions: Parkinson, multiple sclerosis, stroke, history of vestibular disorder, respiratory disease, pregnancy * Radicular symptoms * Not Dutch-speaking * Strong opioids * Neck pain * Smoking history"
NCT03309969,Comparison of Intravascular Ultrasound With Venography in the Diagnosis and Treatment of Iliac Vein Compression Syndrome,Iliac Vein Compression Syndrome,Other, Age: 18 to 90 years  Willing to participate in and sign the informed consent  Patients with suspicious iliac vein stenosis or compression presented by preoperative magnetic resonance venography (MRV)  Patent common femoral vein and/or femoral vein of the study leg  Undergoing iliofemoral venography with the intend to treat potential iliac vein compression syndrome
NCT00483873,Cardiac Arrest Recovery EEG Study,Cardiac Arrest; Arrhythmia,Cardiology,"Inclusion: Cardiac Arrest: * Patients 18 years and older: 1. with cardiac arrest in the hospital and successfully resuscitated, or 2. with cardiac arrest out of the hospital and successfully resuscitated ICD patients: * Patients 18 years and older: 1. Who are undergoing elective procedure in the electrophysiology laboratory for placement of a cardiac defibrillator and who will most likely undergo induction of ventricular arrhythmia as part of the procedure Exclusion: Cardiac Arrest: 1. Cardiac arrest and a known pre-existing cerebral pathology such as brain tumor, cerebral hemorrhage, encephalitis or immediately post-op neurosurgery. 2. CNS infection 3. Skull defects and scalp diseases that are not amenable to standard EEG testing ICD patients: 1. Known pre-existing cerebral pathology such as brain tumor, cerebral hemorrhage, encephalitis or immediately post-op neurosurgery. 2. CNS infection 3. Skull defects and scalp diseases that are not amenable to standard EEG testing"
NCT02517190,"Effects of Repeated Short-term Microgravity During Parabolic Flight Conditions on Neuro-endocrine, Immune and Metabolic Changes",Healthy,Other,"Inclusion: * Healthy volunteers (men or women) * Aged from 18 to 65 * Affiliated to a Social Security system and, for non-French resident, holding a European Health Insurance Card (EHIC) * Who accepted to take part in the study * Who have given their written stated consent * Who participated in the MARS500 experiment * Who has passed a medical examination similar to a standard aviation medical examination for private pilot aptitude. There will be no additional test performed for subject selection. Exclusion: * Person who took part in a previous biomedical research protocol, of which exclusion period is not terminated * Pregnant women"
NCT00839891,A Study to Evaluate How VI-0521 Affect Cardiac Repolarization in Healthy Male and Female Volunteers,Torsades de Pointes,Other,"Inclusion: * Males or females, aged 19 to 50 years, inclusive. * Body mass index (BMI) between 24 and 30 kg/m2, inclusive. * Subjects must be in good health, as determined by a medical history, physical examination, 12-lead ECG and clinical laboratory evaluations. * Women of child-bearing potential should test negative for pregnancy, must use medically acceptable contraceptive methods Exclusion: * Male subjects with a resting QTcB or QTcF value 450 msec, and female subjects with a resting QTcB or QTcF value 470 msec, as measured at the screening visit. * Subjects with clinically significant ECG abnormalities that may interfere with the accurate assessment of the QT interval, including intraventricular conduction delays (QRS >120 msec) and complete bundle branch blocks. * Subjects who have a history of, or risk factors for, Torsades de Pointes (TdP) (eg, heart failure, abnormal serum electrolytes), including a family history of arrhythmia, sudden death or long QT syndrome. * Subjects with known clinically significant arrhythmias or rhythm disturbances observed on the screening ECG and confirmed by a subsequent 24-hour ECG Holter recording. * Subjects who have a supine heart rate (HR) at screening outside 45 to 90 beats per minute (bpm) (measured following at least a 10-minute rest). * Subjects suffering from, or with a history of, one or more of the following conditions: hypertension, impaired glucose tolerance, diabetes mellitus, renal disease, edema, stroke or neurological disorder, rheumatological disorder (including arthritis, joint or tendon abnormalities), pulmonary disorder (including personal history of asthma), cardiovascular disorder (including coronary heart disease, congestive heart failure, cardiomyopathy, and any valvular heart disease), hepatic disorder, or a history of any illness that, in the opinion of the Investigator, might confound the results of the study or pose additional risk to the subject by participation in the study. * Subjects with a history of psychiatric disorders, including bipolar disorder, psychosis, previous episode(s) of major depression or current depression, history of suicidality or suicidal ideation. * Subjects with a history of nephrolithiasis or cholelithiasis. * Subjects with a history of glaucoma, increased intraocular pressure, or use of any medication to treat increased intraocular pressure. * Laboratory values at screening that are outside the normal range for the site unless prior approval is obtained from the VIVUS, Inc. medical monitor or designee. * Subjects who are currently regular users (including recreational use) of any illicit drugs or who have a history of drug (including alcohol) abuse within 1 year of screening. * Subjects who drink excessive amounts (equivalent to >4 cups of brewed coffee per day) of coffee, tea, cola or other caffeinated beverages within the 2 weeks prior to Day -1. * Subjects with a positive urine drug test at screening and/or on Day -1 (eg, cocaine, amphetamines, barbiturates, opiates, benzodiazepines, cannabinoids). * Subjects who consume excessive amounts of alcohol, defined as >3 drinks (beer, wine or distilled spirits) of alcoholic beverages per day, have a history of alcohol abuse, or are unwilling to comply with the restricted use of alcohol during the study. * Subjects with a positive test for ethanol at screening and/or on Day -1."
NCT03658980,Integrating DR Into Mainstream Health System in Bangladesh,Diabetic Retinopathy,Other,"Inclusion: * atleast 18 years of age * Persons with diabetes who are registered with Barishal Diabetes Hospital * Referred to SBMC&H (tertiary hospital) for DR management (screening/treatment), from September 2017 - August 2018 * Persons who did not undergo a Dilated Fundus Examination (DFE) in last 12 months * those who provide informed consent to be included in this study Exclusion: * Below 18 years of age * Persons with diabetes who are registered with Barishal Diabetes Hospital but not referred to SBMC&H (tertiary hospital) for DR management * Persons with diabetes referred to SBMC&H before September 2017 or after August 2018 * Persons who have undergone a Dilated Fundus Examination (DFE) in last 12 months * those who do not provide informed consent to be included in this study"
NCT03051997,Increasing Caregiver Engagement in Juvenile Drug Courts,Substance Abuse,Other,Inclusion Criteria for youth:  Involved in juvenile drug court  Aged 13-17 years  Youth is willing to participate  At least one caregiver is willing to participate in the youth's treatment  Fluent in English or Spanish Exclusion Criteria for youth:  Diagnosed with intellectual disability or autism spectrum disorder Inclusion Criteria for caregivers:  Caregiver of youth involved in juvenile drug court  Caregiver is willing to participate  Fluent in English or Spanish Exclusion Criteria for caregivers:  Diagnosed with intellectual disability or autism spectrum disorder Inclusion Criteria for therapists:  Providing substance abuse treatment to a youth in juvenile drug court Exclusion Criteria for therapists:  None Inclusion Criteria for Juvenile Drug Court Personnel:  Personnel working in juvenile drug court Exclusion Criteria for Juvenile Drug Court Personnel:  None
NCT00532142,The ROVO Study: Radial Optic Neurotomy for CVO,Central Retinal Vein Occlusion,Other,"Inclusion: * Onset of CVO not longer than 12 months * On FLA 1. nonperfused - (greater than 10 disc area of nonperfusion) 2. perfused - visual acuity lower than 0.1 Snellen,or 3. perfused with no improvement of visual acuity over 4 weeks) Exclusion: * • Dense cataract* (grade 3 and 4) which precludes judgement of the fundus. * Pregnancy * Allergy against Fluoresceine or Indocyanine green * Unable to come for follow up visit * Presence of other severe retinopathy or * Presence of advanced optic atrophy or uncontrolled glaucoma. * Visual acuity higher than 0.5 Snellen."
NCT06424782,Therapeutic Effect of the Natural Mineral Water of the Well B-308 OKK in Győr (Gyirmót) on Knee Osteoarthrosis,Knee Osteoarthritis,Other,"Inclusion: * Knee osteoarthrosis that has existed for at least 3 months * Age between 50 and 80 years * Willingness to participate in 3-week outpatient rehabilitation treatment * Pain in the knee joint lasting at least 3 months and at least 5 days a week * At least mild pain during selection (1 point on the Likert scale) * Does not have a serious disability Exclusion: * Any kind of physiotherapy treatment in the last 2 months (except home gymnastics) * Any previous knee joint surgery * Any trauma to the knee or hip joint in the 1 year prior to the examination * Knee arthroscopy performed within 3 months prior to the examination * Intra-articular corticosteroid treatment of the affected knee in the last 3 months * Palpable Baker's cyst * Any hip joint or spine surgery within a year before the examination * Intra-articular hyaluronic injection within 2 months before the examination * Appearance of lumbar radiculopathy * Presence of serious internal medicine disease, urogenital or other diseases * Uncooperative or psychoneurotic patients * Lumbago, sciatica; and any other surgery or previous fracture in the hip joint * Subluxation, luxation, algodystrophy, fibromyalgia, gout * Balneotherapy in the last 6 months * Systemic corticosteroid treatment in 1 month before the examination * Starting the treatment of osteoarthritis SYSADOA (symptomatic slow-acting drugs for osteoarthritis) in 3 months before the examination"
NCT03167424,Restenosis Intrastent: Treatment of Bioresorbable Vascular Scaffolds Restenosis,Coronary In-stnent Restenosis,Cardiology,Inclusion: PATIENT * Age > 20 and 50% diameter stenosis on visual assessment) * Previous stent location known Exclusion: PATIENT * Inclusion in other clinical research protocol * Refuse to sign Informed Consent
NCT03840603,Impact on PCT+ FilmArray RP2 Plus Use in LRTI Suspicion in Emergency Department,Respiratory Tract Infections,Infectious Disease,"Inclusion: * 1. Subject is ≥ 18 years of age attending the ED with LRTI symptom defined as at least one among: 1. sweats, chills, body aches and pain, temperature >38°C) and at least one among: 2. cough, sputum production, dyspnea, chest pain, altered breath sounds at auscultation. * 2. Subject signs informed consent Exclusion: 1. Subject is a prisoner 2. Subject is a Pregnant 3. Subject has no social insurance 4. Subject is enrolled in end of life care 5. Subject refuses to participate in study procedures 6. Subject is already enrolled (each patient will only be tested one time with the FilmArray® RP2plus) 7. Subject has a contraindication (per the discretion of the attending physician) to a nasopharyngeal swab (for example, nose bone fracture or recent history of maxilla-facial surgery)"
NCT03270813,RAGE-Control: Teaching Emotional Self-regulation Through Videogame Play,Anger; Aggression,Other,"Inclusion: * Problems with anger and/or aggression * Score of at least 4/10 on phone screen with parents measuring anger and aggression Exclusion: * Changes in dosing of psychotropic medications within the 8 weeks prior to the start of the study, or anticipated medication changes during the study. * Starting therapy within the 8 weeks prior to starting the study, or anticipated new therapy beginning during the study. * Actively participating in any type of Cognitive Behavioral Therapy for less than 12 weeks and/or attending Cognitive Behavioral Therapy weekly or more. * Intellectual disability (IQ < 80) * Suicidal ideation * Homicidal ideation * Psychosis/meets criteria for psychotic disorder"
NCT02732041,Asynchrony During Mechanical Ventilation in Patients With Acute Respiratory Distress Syndrome,"Respiratory Distress Syndrome, Adult; Ventilator-Induced Lung Injury",Pulmonology,Inclusion: * Acute Respiratory Distress Syndrome according to Berlin definition * Intubation and mechanical ventilation within 72 hours of inclusion Exclusion: * Known severe neuromuscular disease * Continuous neuromuscular blocking agents infusion
NCT00454974,Pilot Study of Wearable Artificial Kidney,Renal Failure,Other, End stage renal failure  Regular haemodialysis  Cardiovascular stability  Stable vascular access
NCT01164397,Efficiency of Rosuvastatin Versus the Fixed Combination of Ezetimibe/Simvastatin in Outpatients,Dyslipidemia,Other,"Inclusion: * Dislipidemic population treated with rosuvastatin or ezetimibe/simvastatin for at least for 8 weeks * Who have completed at least 80% of the treatment * To have determinations at least of CT, TG C-LDL and CHDL before starting treatment and after 8 weeks of taking the medicine Exclusion: * Initiating different therapy lipid lowering to Rosuvastatin or Ezetimibe/Simvastatin"
NCT06754969,Does RPNI Reduce Incidence of Neuroma Formation Following Sural Nerve Biopsy,Neuroma of Lower Limb,Neurology,"Inclusion: * Patient 18 years old and older who are referred for sural nerve and muscle biopsy to the University of British Columbia Division of Plastic Surgery from January 2025 onwards for diagnostic or prognostic clarification of a medical condition. Exclusion: * Patients with previous nerve trauma (traumatic injury, surgery, or repeat biopsy) of biopsied nerve."
NCT01934556,A Safety and Efficacy Trial of a Treat and Extend Protocol Using Ranibizumab With and Without Laser Photocoagulation for Diabetic Macular Edema,Diabetic Macular Edema,Other,"Inclusion: * Ability to provide written informed consent and comply with study assessments for the full duration of the study * Age > 18 years of age Patient related considerations * For sexually active women of childbearing potential, agreement to the use of an appropriate form of contraception (or abstinence) for the duration of the study * Although no birth control method is 100% effective, the following are considered effective means of contraception: surgical sterilization, use of oral contraceptives, barrier contraception using either a condom or diaphragm with spermicidal gel, an intrauterine device, or contraceptive hormone implant or patch. A patient's primary care physician, obstetrician, or gynecologist should be consulted regarding an appropriate form of birth control. * Ability and willingness to return for all scheduled visits and assessments Disease related considerations * The presence of center-involving diabetic macular edema on clinical exam and SDOCT * Best corrected visual acuity in the study eye, using ETDRS testing, between 20/25 and 20/320 (Snellen equivalent), inclusive. * Clear ocular media and adequate pupillary dilation to permit good quality fundus imaging. Exclusion: * General Exclusion Criteria * Pregnancy (positive urine pregnancy test) or lactation. * Premenopausal women not using adequate contraception. The following are considered effective means of contraception: surgical sterilization or use of oral contraceptives, barrier contraception with either a condom or diaphragm in conjunction with spermicidal gel, an IUD (Intrauterine Device) , or contraceptive hormone implant or patch. * Any other condition that the investigator believes would pose a significant hazard to the subject if the investigational therapy were initiated * Participation in another simultaneous medical investigation or trial Ocular Exclusion Criteria Prior Ocular Treatment * History of active proliferative diabetic retinopathy in the study eye on clinical exam * History of vitrectomy surgery, submacular surgery, or other intraocular surgical intervention for diabetic macular edema in the study eye * Any previous intravitreal drug delivery (e.g., intravitreal corticosteroid injection, anti-VEGF drugs including ranibizumab, or device implantation) in the study eye within 90 days of the screening visit. * History of prior laser macular photocoagulation more than 90 days prior to screening will be eligible for study inclusion. However, if the investigator does not feel that additional laser photocoagulation can be safely performed or would benefit the patient, then the eye in consideration will be excluded. * Evidence of vitreomacular interface abnormality or epiretinal membranes which may be responsible for macular edema Concurrent Ocular Conditions • Any concurrent intraocular condition in the study eye (e.g., cataract or macular degeneration) that, in the opinion of the investigator, could either: Require medical or surgical intervention during the 24-month study period to prevent or treat visual loss that might result from that condition; or if allowed to progress untreated, could likely contribute to loss of at least 2 Snellen equivalent lines of BCVA (Best Corrected Visual Acuity) over the 24-month study period. * Active intraocular inflammation (grade trace or above) in the study eye * Current vitreous hemorrhage in the study eye * History of rhegmatogenous retinal detachment or macular hole (Stage 3 or 4) in the study eye * Active infectious conjunctivitis, keratitis, scleritis, or endophthalmitis in either eye * Aphakia or absence of the posterior capsule in the study eye * Intraocular surgery (including cataract surgery) in the study eye within 3 months preceding Day 0 * Uncontrolled glaucoma in the study eye (defined as IOP (Intraocular Pressure) ≥ 30 mmHg despite treatment with anti-glaucoma medication) * History of glaucoma-filtering surgery in the study eye * History of corneal transplant in the study eye * History of pars plana vitrectomy Concurrent Systemic Conditions * Any history of use of systemic anti-VEGF (Vascular Endothelial Growth Factor) agents * Uncontrolled blood pressure (defined as systolic > 180 mmHg and/or diastolic > 110 mmHg while patient is sitting) If a patient's initial reading exceeds these values, a second reading may be taken 30 or more minutes later. If the patient's blood pressure needs to be controlled by antihypertensive medication, the patient can become eligible if medication is taken continuously for at least 30 days prior to Day 0. * Atrial fibrillation not managed by patient's primary care physician or cardiologist within 3 months of screening visit * Women of childbearing potential not using adequate contraception (as defined in the inclusion criteria). A woman is considered not to be of childbearing potential if she is postmenopausal, defined by amenorrhea for at least 1 year in a woman > 45 years old; or has undergone hysterectomy and/or bilateral oophorectomy. * History of stroke within the last 3 months of screening visit * History of other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use an investigational drug or that might affect interpretation of the results of the study or renders the patient at high risk for treatment complications * Current treatment for active systemic infection * Active malignancy * History of allergy to fluorescein, not amenable to treatment * Inability to obtain fundus photographs or fluorescein angiograms of sufficient quality to be analyzed and graded by the reading center * Inability to comply with study or follow-up procedures * Previous participation in any studies of investigational drugs within 1 month preceding Day 0 (excluding vitamins and minerals)"
NCT01846013,Increasing Workplace Physical Activity in Sedentary Office Workers,Sit-Stand Workstations,Other,Inclusion: * Sedentary adults who use a single computer workstation for the majority of their workday * Work full time (at least 35 hours per week) * Must have ability to safely begin a standing and/or walking protocol with no adverse side effects Exclusion: * Musculoskeletal or joint problems * Severe autoimmune conditions * Varicose veins that may cause pain * Women who are pregnant
NCT00184691,Growth Hormone Treatment of Children Born With Retarded Intrauterine Growth at Age 2-5 Years,Foetal Growth Problem; Small for Gestational Age,Other,Inclusion: * IUGR defined as birth length and/or weight below the lower limit ( 1 mg/dL
NCT04323176,2nd AC+: New Village Model,Aging; Hiv; Loneliness; Social Isolation,Infectious Disease,Inclusion: * Lives in Central San Diego * Consents to participate * Willing to sign Village social contract * No plans to move out of Central San Diego in the next year * Speaks English Exclusion: * Severely cognitively impaired as indicated by < 10 on mini mental state examination * History of a violent felony or fraud in the past 10 years * Not willing to consent to participation
NCT04044417,Curcumin-Simvastatin-EDTA in the Treatment of Periodontitis,Periodontitis,Other,"Inclusion: * Patient suffering at least a single posterior 2-3 wall periodontal Pocket of depth ≥ 5 mm, attachment loss ≥3 mm, intrabony component ≥3 mm, plaque index ≤1 (Sillness and Loe, 1964) and sulcus bleeding index ≤1 (Mühlemann & Son, 1971). All these criteria were determined after phase I conventional periodontal therapy. * Systemically healthy as evidenced by burket's oral medicine health history question questionnaire (Glick et al., 2008). * Patients available during follow-up periods Exclusion: * Smoking * Patient unwilling to comply with periodontal hygienic instructions * Patients under any long-term chronic medication * Vulnerable individuals"
NCT06892405,Airway US in Predicting Difficult Pediatric Laryngoscopy,Airway Complication of Anesthesia,Other,"Inclusion: * Gender both males and females * ASA Class I and II * Age 2 years to 6 * Children scheduled for elective surgery under general anesthesia requiring orotracheal intubation after classical laryngoscopy. Exclusion: * Congenital upper airway malformation, * Head and neck swellings, * Scars, * Radiation to the neck, * Tracheotomy,"
NCT02200796,"Role of Dietary Protein on Satiety, Food Intake and Thermic Effect of Food",Overweight; Obesity,Other,"Inclusion: * Boys and girls between the ages of 9 and 14 y * Only peri-pubertal girls * Normal body weight (between the 5th and 85th BMI percentile for age and gender) * OW/OB (>85th BMI percentile for age and gender) Exclusion: * Food sensitivities * Food allergies * Dietary restrictions * Health, learning, emotional or behavioural problems * On any medication"
NCT07184827,Evaluate the Efficacy and Safety of U101 Oral Capsules in the Prevention of Uncomplicated rUTIs in Women,Recurrent Urinary Tract Infections in Women,Infectious Disease,"Inclusion: 1. Provide a signed informed consent form. 2. Non-pregnant, non-nursing females ≥ 20 and 1.5 x upper limit of normal (ULN). 4. Serum creatinine > 1.5 x ULN. 5. Prothrombin time (PT) or INR > 1.2 x ULN. 6. Platelet counts 8.0%. 9. Positive test for hepatitis B (both HBsAg and HBeAg), hepatitis C (anti-HCV antibody) or HIV (anti-HIV antibody). 10. Symptoms suggestive of a systemic inflammatory response (fever > 38℃ or WBC count > 12,000) at the screening. 11. A major functional or anatomical abnormality of the urogenital tract (e.g., renal cell carcinoma, outlet obstruction, etc.). 12. Diagnosis of pelvic organ prolapse ≥ grade 2 (according to pelvic organ prolapse quantification POP-Q classification) without any treatment within 6 months of the screening visit. 13. Diagnosis of complicated UTIs within 6 months of the screening visit. 14. Residual urine volume > 100 mL within a month of the screening visit. 15. History of interstitial cystitis, pelvic inflammatory disease, or chronic pelvic pain syndrome. 16. Having any of the following procedures within a week of the screening: urinary catheterization (e.g., Foley catheter), ureteral stent, percutaneous nephrostomy, or cystostomy. 17. Intravesical instillation of hyaluronic acid within 6 months of the screening visit. 18. Treatment with pentosan polysulfate sodium (PPS) within 6 months of the screening visit. 19. Use of antibiotic prophylaxis for rUTI within a month of the screening visit. 20. Use of local hormone therapy (cream, gel, insert, ring, or tablets) in urogenital areas within a month of the screening. 21. Any history of thrombocytopenia, hemophilia, or bladder cancer; history of endoscopy-confirmed gastrointestinal ulcers within 3 years prior to randomization. 22. Active malignancy (under intensive cancer treatment or considered in progression) or a history of any malignancy involving the pelvic cavity within 5 years prior to randomization, with the exception of adequately treated basal cell carcinoma and cervical cancer in-situ. Subjects in stable condition will be evaluated and discussed individually with the investigator. 23. Immunocompromised or history of organ transplant. 24. History of allergies to pentosan polysulfate sodium. 25. Having planned major surgery within 24 weeks after the study. 26. Participation in any interventional clinical trial within 30 days of the screening visit. 27. Other significant medical problem(s) or intercurrent acute illness(es) that in the opinion of the Investigators, would make participation in the study unsafe, complicate the interpretation of study outcome data, or otherwise interfere with achieving the study objective. 28. Subjects who are illiterate. 29. Subjects having a family history of macular degeneration or having been diagnosed with macular degeneration (except for those with asymptomatic age-related macular degeneration) ."
NCT05721261,Regeneration of Acutely Injured Nerves With Temporary Electrical Stimulation,Nerve Injury,Other,Inclusion: * Peripheral nerve injury Exclusion: * Peripheral neuropathy * Patients with any active implanted device
NCT03024905,Project to Use Community Health Workers to Reduce Maternal Deaths,Maternal Mortality; Access to Health Care,Other,"Inclusion: 1. Women must be pregnant. 2. Women must live in Rorya District, but not in Shirati Town. 3. Women must deliver in Rorya District . Exclusion: 1. Women who live outside or deliver outside of Rorya District. 2. Women who deliver preterm, before they have exposure to all the interventions."
NCT00639873,Artemisinin Resistance in Bangladesh,Malaria,Other,"Inclusion: 1. Acute symptomatic falciparum malaria infection as determined by malaria smear with a parasite density of 1,000 to 100,000 asexual parasites/uL as determined on the screening smear with fever (defined as ≥37.5C), or reported history of fever within the last 48 hours. 2. Age: 8-65 years old 3. All females between the age of 12 and 50 are required to have a negative human chorionic gonadotropin (hCG) pregnancy test (urine). All females of childbearing potential (not surgically sterile, or less than two years menopausal) are required to use an acceptable method of contraception throughout the study 4. Written informed consent obtained 5. Willing to stay under close medical supervision for the study duration of 42 days 6. Otherwise healthy outpatients Exclusion: 1. Pregnant women, nursing mothers, or women of childbearing potential who do not use an acceptable method of contraception 2. Mixed malaria infection on admission by malaria smear 3. A previous history of intolerance or hypersensitivity to the study drugs or to drugs with similar chemical structures 4. Malaria drug therapy administered in the past 30 days by history 5. History of significant cardiovascular, liver or renal functional abnormality or any other clinically significant illness, which in the opinion of the investigator would place them at increased risk. 6. Symptoms of severe vomiting (no food or inability to take food during the previous 8 hours). 7. Signs or symptoms of severe malaria (as defined by WHO 2000) 8. Unable and/or unlikely to comprehend and/or follow the protocol"
NCT00106613,A Research Study for Patients With Metastatic Renal Cell Carcinoma,"Carcinoma, Renal Cell; Neoplasm Metastasis",Other,"Inclusion: Patients must fulfill all of the following criteria to be eligible for study participation: * Age ≥ 18 years; * Histologically confirmed Renal Cell Carcinoma (RCC); * Metastatic disease, with measurable lesions according to the Response Evaluation Criteria in Solid Tumors (RECIST); * Failure of prior cytokine therapy; * Documented progressive disease; Exclusion: Patients are ineligible for entry if any of the following criteria are met: * Significant cardiac disease including congestive heart failure, history of myocardial infarction within one year, uncontrolled dysrhythmias, or poorly controlled angina * History of serious ventricular arrhythmia * Corrected QT interval (QTc) ≥ 500 msec * Known infection with Human Immunodeficiency Virus (HIV), Hepatitis B, or Hepatitis C; * Previous extensive radiotherapy involving ≥ 30% of bone marrow * Coexistent second malignancy or history of prior malignancy within previous 5 years"
NCT00002889,Radiation Therapy With Androgen Suppression in Treating Patients With Prostate Cancer,Prostate Cancer,Oncology,"DISEASE CHARACTERISTICS: Histologically confirmed adenocarcinoma of the prostate AJCC stage T1b-T4b, N0 or Nx, M0 Transrectal, transperineal, or transurethral biopsy required PATIENT CHARACTERISTICS: Age: 30 and over Performance status: CALGB 0-2 Hematopoietic: Not specified Hepatic: Not specified Renal: Not specified Other: The following may increase the risk of protocol treatment: Serious intercurrent medical illness that might compromise patient safety Active acute infection requiring antibiotics Suppression therapy for chronic urinary tract infection allowed Uncontrolled or severe cardiovascular disease Psychiatric conditions that prevent compliance or informed consent PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: No prior chemotherapy for carcinoma of the prostate Endocrine therapy: No prior androgen deprivation therapy (medical or surgical) Radiotherapy: No prior radiation therapy for carcinoma of the prostate Surgery: No prior surgical androgen deprivat"
NCT00468559,Phase 3/Safety & Efficacy of Esomeprazole in Infants,Gastroesophageal Reflux Disease (GERD),Other,"Inclusion: * patients' parents must sign the informed consent prior to the beginning of any study-related procedures (according to local regulations) * patients must have symptoms at study entry and have a clinical diagnosis of suspected GERD, symptomatic GERD, or GERD proven by a test called an endoscopy, a test using a long tube inserted in the body for diagnostic exams Exclusion: * patients who have used a PPI (proton pump inhibitors; used to reduce the amount of acid in the stomach) within 7 days before enrollment in the open label treatment phase (Day 0) * patients with a history of acute life-threatening event"
NCT01020240,Physiotherapy in Postpartum After a Cesarean,Postpartum Period,Other,Inclusion: * have between 15 and 35 yeas old * has realize an emergency or elective cesarean * being in immediate puerperium and did not have receive any orientation Exclusion: * complications in delivery and postpartum * complications with the baby * physicologics disease
NCT03151876,Chidamide Combined With Clad/Gem/Bu With AutoSCT in R/R Diffuse Large B Cell Lymphoma,Lymphoma,Oncology,"Inclusion: 1. Patients with primary refractory or recurrent diffuse large B cell lymphoma that do not qualify for treatment protocols of higher priority. 2. Relapsed patients should respond to 2nd or 3rd line salvage chemotherapy and attain at least PR before recruitment. 3. Adequate renal function, as defined by estimated serum creatinine clearance >/=50 ml/min and/or serum creatinine /= 50% of expected corrected for hemoglobin. 8. Adequate cardiac function with left ventricular ejection fraction >/= 50%. No uncontrolled arrhythmias or symptomatic cardiac disease. 9. Performance status 0-1. 10. Negative Beta diffusing capacity of lung for carbon monoxide (HCG) text in a woman with child-bearing potential, defined as not post-menopausal for 12 months or no previous surgical sterilization Exclusion: 1. Central nervous system lymphoma 2. Patients relapsed after ASCT 3. Bone marrow was involved by lymphoma 4. Patients with active hepatitis B or C(HBV DNA >/=10,000 copies/mL). 5. Active infection requiring parenteral antibiotics 6. HIV infection, unless the patient is receiving effective antiretroviral therapy with undetectable viral load and normal cluster of differentiation 4 (CD4) counts 7. Evidence of either cirrhosis or stage 3-4 liver fibrosis in patients with chronic hepatitis C or positive hepatitis C serology. 8. Patients with a cQT longer than 500 ms"
